UNITED THERAPEUTICS Corp (UTHR)

504.49 -9.33 (-1.82%)

As of 2026-03-03 13:29:44 EST

United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.

Traded asNasdaq: UTHR
ISINUS91307C1027
CIK0001082554
LEI5299005C4HZL4UWROC14
EIN521984749
SectorBiotechnology
IndustryPharmaceutical Preparations
CEO—
Employees1,168
Fiscal Year End1231
Address1000 SPRING ST, SILVER SPRING, MD, 20910
Phone3016089292
Websitehttps://unither.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
UTHRUNITED THERAPEUTICS Corp2026-03-03 13:29:44504.49-9.33-1.82
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
UTHR0001082554UNITED THERAPEUTICS CorpUS91307C10275299005C4HZL4UWROC14521984749Nasdaq2834Pharmaceutical Preparations1231DE1000 SPRING STSILVER SPRINGMD20910UNITED STATESUS30160892921000 SPRING ST, SILVER SPRING, MD, 209101000 SPRING ST, SILVER SPRING, MD, 20910—Biotechnology1996—1,168https://unither.com11,233,042,52376,452,25343,827,686United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.2026-02-26 15:46:26
This is a preview of the latest data. Subscribe to access the full data.
UTHR Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
UTHR Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202511,233,042,523-922,492,911-7.589143,827,686-1,084,491-2.4147
202412,155,535,4343,017,303,53333.018544,912,177-2,146,368-4.5611
20239,138,231,901-1,394,108,620-13.236547,058,545756,8891.6347
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Michael BenkowitzPresident20241,186,539——3,060,00036,12813,893,389
Paul MahonExecutive Vice President, General Counsel2024940,000——1,974,00029,5406,963,308
Martine RothblattChairperson20241,512,401——5,625,00012,20023,009,609
James EdgemondChief Financial Officer, Treasurer2024860,577——1,968,75034,4559,164,549
Paul MahonExecutive Vice President, General Counsel2023940,000——1,460,23441,0865,153,601
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20251,400
20241,305
20231,168
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue3,182,700,0002,877,400,0002,327,500,000
Cost Of Revenue384,400,000309,700,000257,500,000
Gross Profit2,798,300,0002,567,700,0002,070,000,000
Research And Development Expenses550,000,000481,000,000408,000,000
General And Administrative Expenses755,800,000709,700,000477,100,000
Operating Expenses1,690,200,0001,500,400,0001,142,600,000
Operating Income1,492,500,0001,377,000,0001,184,900,000
Net Income1,334,700,0001,195,100,000984,800,000
Earnings Per Share Basic30.1326.4421.04
Earnings Per Share Diluted27.8624.6419.81
Weighted Average Shares Outstanding Basic44,300,00045,200,00046,800,000
Weighted Average Shares Outstanding Diluted47,900,00048,500,00049,700,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents1,557,100,0001,697,200,0001,207,700,000
Marketable Securities Current1,363,200,0001,569,800,0001,786,400,000
Accounts Receivable350,200,000279,300,000278,900,000
Inventories183,100,000157,900,000111,800,000
Non Trade Receivables———
Other Assets Current248,900,000169,700,000166,200,000
Total Assets Current3,702,500,0003,873,900,0003,551,000,000
Marketable Securities Non Current1,776,700,0001,475,300,0001,909,800,000
Property Plant And Equipment1,729,700,0001,222,400,0001,045,400,000
Other Assets Non Current196,900,000222,100,000151,800,000
Total Assets Non Current1,759,300,0001,252,300,0001,069,800,000
Total Assets7,880,000,0007,364,000,0007,167,000,000
Accounts Payable7,100,0006,000,0005,600,000
Deferred Revenue———
Short Term Debt0300,000,000400,000,000
Other Liabilities Current72,600,00082,600,00071,000,000
Total Liabilities Current560,600,000738,100,000804,400,000
Long Term Debt0——
Other Liabilities Non Current223,200,000181,900,00077,800,000
Total Liabilities Non Current223,200,000181,900,000377,800,000
Total Liabilities783,800,000920,000,0001,182,200,000
Common Stock800,000800,000700,000
Retained Earnings8,556,900,0007,222,200,0006,027,100,000
Accumulated Other Comprehensive Income900,000-3,400,000-12,800,000
Total Shareholders Equity7,096,200,0006,444,000,0005,984,800,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization85,600,00072,500,00053,200,000
Share Based Compensation Expense147,700,000144,000,00039,100,000
Other Non Cash Income Expense19,700,00024,300,0004,900,000
Change In Accounts Receivable70,900,000400,00058,500,000
Change In Inventories52,600,00046,900,00013,600,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable97,900,00042,700,00057,100,000
Change In Other Liabilities80,900,00055,600,00082,800,000
Cash From Operating Activities1,561,200,0001,327,100,000978,000,000
Purchases Of Marketable Securities3,405,400,0001,646,100,0002,514,300,000
Sales Of Marketable Securities1,861,600,000831,800,0000
Acquisition Of Property Plant And Equipment520,500,000246,500,000230,400,000
Acquisition Of Business0089,200,000
Other Investing Activities———
Cash From Investing Activities-551,300,000417,200,000-719,600,000
Tax Withholding For Share Based Compensation16,600,00012,200,00013,800,000
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock1,000,000,0001,000,000,00014,700,000
Issuance Of Long Term Debt———
Repayment Of Long Term Debt500,000,000400,000,000100,000,000
Other Financing Activities———
Cash From Financing Activities-1,150,000,000-1,254,800,000-11,900,000
Change In Cash-140,100,000489,500,000246,500,000
Cash At End Of Period1,557,100,0001,697,200,0001,207,700,000
Income Taxes Paid313,300,000400,600,000332,500,000
Interest Paid13,500,00040,200,00056,000,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share30.1326.4421.04
Price To Earnings Ratio16.171613.344910.451
Earnings Growth Rate13.956125.665431.6646
Price Earnings To Growth Ratio1.15870.520.3301
Book Value Per Share160.1851142.5664127.8803
Price To Book Ratio3.04182.47491.7195
Ebitda1,753,100,0001,711,100,0001,429,800,000
Enterprise Value20,028,075,000——
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0——
Capital Expenditures592,900,000249,500,000237,100,000
Free Cash Flow968,300,0001,077,600,000740,900,000
Return On Equity0.18810.18550.1646
One Year Beta0.37490.3970.504
Three Year Beta0.40520.40560.4855
Five Year Beta0.44580.57860.6108
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Olian Judy D.Director2026-02-27200D4,845
CAUSEY CHRISTOPHERDirector2026-02-251,000A5,190
CAUSEY CHRISTOPHERDirector2026-02-251,000D4,190
CAUSEY CHRISTOPHERDirector2026-02-251,000D6,320
BENKOWITZ MICHAELPRESIDENT AND COO2026-02-239,375A9,375
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Lisa McClain2025-11-21MI09Purchase2025-10-30Spouse$1,001 - $15,000
Lisa McClain2025-11-21MI09Sale2025-10-30Spouse$1,001 - $15,000
Lisa McClain2025-11-21MI09Sale2025-10-31Spouse$1,001 - $15,000
Lisa McClain2025-08-13MI09Purchase2025-06-11Spouse$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
TOBAM2025-12-314,803,0009,857487.2679
Wick Capital Partners, LLC2025-12-31297,223610487.2508
Anchor Investment Management, LLC2025-12-31136,430280487.25
DGS Capital Management, LLC2025-12-31409,777841487.2497
Bell Investment Advisors, Inc2025-12-3120,95243487.2558
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Lazard Active ETF Trust2025-12-31Lazard US Systematic Small Cap Equity ETFSYZ602293,324.50.5305
PIMCO Equity Series2025-12-31PIMCO RAFI Dynamic Multi-Factor U.S. Equity ETFMFUS798388,825.50.1848
Advisor Managed Portfolios2025-12-31Optimize Strategy Index ETFOPTZ1,070521,357.50.2603
RYDEX SERIES FUNDS2025-12-31Class CRYCFX4,1372,015,753.251.8493
RYDEX SERIES FUNDS2025-12-31Class ARYBOX4,1372,015,753.251.8493
This is a preview of the latest data. Subscribe to access the full data.